FDA Inspection 1215682 — Lori Gawron
The FDA completed an inspection of Lori Gawron on August 18, 2023 in Salt Lake City, UT. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 18, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Salt Lake City, UT (United States)
Additional Details
Clinical Investigator (CI)